FDA Approved: RUXIENCE — Original Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

FDA approved Ruxience (rituximab-pvvr) from Pfizer as a biosimilar to rituximab, under an original application; the approval covers multiple indications for B-c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Granulomatosis with Polyangiitis
• Microscopic Polyangiitis
• Non-hodgkin Lymphoma
• Rheumatoid Arthritis
• Small Lymphocytic Lymphoma

Drugs mentioned

• RUXIENCE (RITUXIMAB-PVVR)

Snippet

ORIG AP for RUXIENCE (RITUXIMAB-PVVR)